Celgene to acquire Juno for $9b

Jan 22, 2018

Celgene Corp. announced this week that it is buying Juno Theraputics, in a deal valued near $9 billion.

The deal is one of the largest ever for Celgene, which is expected to struggle in the coming years amid rising competition against its high-selling blood cancer drug, Revlimid. 

Juno is best known for its personalized cancer treatments called CAR T-cell therapies. Juno’s JCAR017 is the closest of all the treatments to receiving regulatory approval. Celgene reported that it expects global sales to hit $3 billion for the treatment.

The purchase, which is the second by Celgene this year, sends a clear message that the company plans to expand its footing in the cancer treatment space.

Read the full Bloomberg report. 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments